Equities

SCI Pharmtech Inc

4119:TAI

SCI Pharmtech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)88.80
  • Today's Change0.50 / 0.57%
  • Shares traded53.75k
  • 1 Year change-6.49%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SCI Pharmtech, Inc. is a Taiwan-based company principally engaged in the processing, manufacture and sales of Active Pharmaceutical Ingredients (APIs). The Company's main products include APIs, API intermediates and special and precision chemicals. The Company distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others

  • Revenue in TWD (TTM)1.25bn
  • Net income in TWD138.47m
  • Incorporated1987
  • Employees241.00
  • Location
    SCI Pharmtech IncNo. 186-2, Neighborhood 16, Hai-Hu-TsunTAOYUAN 338TaiwanTWN
  • Phone+886 33543133
  • Fax+886 33543483
  • Websitehttp://www.sci-pharmtech.com.tw
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sinphar Pharmaceutical Co Ltd3.01bn361.33m5.95bn984.0015.271.7710.111.982.152.1517.9318.610.48642.286.06--5.71-0.01477.67-0.020339.0237.4911.74-0.03441.4437.220.359979.703.725.9867.01111.883.3158.49
Formosa Pharmaceuticals Inc133.70m-298.43m5.98bn----5.92--44.75-2.22-2.220.99637.540.0803--1.61---17.91-40.34-19.62-44.2186.96---223.16-2,488.28----0.0277--2,270.49--20.75---42.98--
Panion & BF Biotech Inc2.01bn101.27m7.62bn321.0075.314.1127.953.791.181.1823.4221.620.61851.739.66--3.124.084.825.6352.6652.375.045.930.869910.620.287111.06-21.545.96-57.65-13.4735.39-3.23
SCI Pharmtech Inc1.25bn138.47m10.61bn241.0078.342.1032.128.481.131.1312.7042.260.20441.613.83--2.266.902.548.2627.7538.1811.0619.851.78802.610.182642.3833.83-9.10-4.55-8.0044.67-16.35
Standard Chem & Pharm Co Ltd6.61bn854.07m11.63bn1.13k13.632.007.361.764.784.7836.9732.570.57532.316.33--10.479.6820.2817.6143.8643.7518.2017.021.49--0.085660.346.6411.802.3917.4029.9712.47
Adimmune Corp1.66bn-607.92m11.64bn564.00--2.27--7.03-1.44-1.443.9311.920.18481.254.04---8.270.6867-10.190.773927.8230.11-44.753.041.99-24.750.328432.80-20.7216.77-319.91--38.05--
Formosa Laboratories Inc4.69bn255.94m11.95bn480.0047.071.5919.912.552.112.1138.9062.490.34791.494.42--0.70672.680.96893.6144.3035.402.038.751.180.89220.315527.3815.8010.16-69.16-6.52-11.6032.22
Data as of Sep 20 2024. Currency figures normalised to SCI Pharmtech Inc's reporting currency: Taiwan Dollar TWD

Institutional shareholders

0.49%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 05 Sep 2024485.97k0.41%
Dimensional Fund Advisors Ltd.as of 30 Jun 202448.23k0.04%
SSgA Funds Management, Inc.as of 05 Sep 202443.16k0.04%
DFA Australia Ltd.as of 31 Jul 20248.01k0.01%
Pennsylvania State Employees' Retirement Systemas of 31 Dec 20210.000.00%
More ▼
Data from 31 Dec 2021 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.